Product Description
Mechanisms of Action: M1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Chile | Ecuador | Egypt | Indonesia | Japan | Malaysia | Mexico | Philippines | Russia | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: ONO Pharm
Company Location: CHUO-KU OSAKA 541 JA M0
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Overactive Bladder
Phase 2: Overactive Bladder|Chronic Obstructive Pulmonary Disease
Phase 1: Urinary Incontinence, Urge|Overactive Bladder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
178-MA-3146 | N/A |
Completed |
Overactive Bladder |
2020-03-30 |
|
CTR20191280 | N/A |
Completed |
Urinary Incontinence, Urge |
2019-09-17 |
|
178-MA-3147 | N/A |
Completed |
Overactive Bladder |
2019-09-13 |
|
CTR20191340 | N/A |
Completed |
Urinary Incontinence, Urge |
2019-09-04 |